

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Ishikawa

RRID:CVCL_2529

Type: Cell Line

Proper Citation

RRID:CVCL_2529

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2529

Proper Citation: RRID:CVCL_2529

Description: Cell line Ishikawa is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Type I endometrial adenocarcinoma

Defining Citation: [PMID:4031568](#), [PMID:10381137](#), [PMID:12703541](#), [PMID:15053063](#), [PMID:15901131](#), [PMID:20215515](#), [PMID:20218740](#), [PMID:20944090](#), [PMID:22710073](#), [PMID:23255909](#), [PMID:25877200](#), [PMID:27397505](#), [PMID:36396974](#)

Comments: Miscellaneous: DepMap data are indicated for Ishidisconkawa (Heraklio) 02 ER- (CVCL_6543), but the referenced ECACC provider corresponds to Ishikawa (CVCL_2529)., Population: Japanese., Part of: ENCODE project common cell types; tier 3.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Ishikawa

Synonyms: ISHIKAWA, ISHI

Cross References: BTO:BTO_0003041, CLO:CLO_0037163, EFO:EFO_0005718, ArrayExpress:E-MTAB-3610, BCRJ:0364, BioSample:SAMN03471030, cancercellines:CVCL_2529, CCRID:1101HUM-PUMC000686, Cell_Model_Passport:SIDM00038, ChEMBL-Cells:ChEMBL3307675, ChEMBL-Targets:ChEMBL614649, CLS:305262, Cosmic:713475, Cosmic:713499, Cosmic:809129, Cosmic:846174, Cosmic:1070811, Cosmic:1152553, Cosmic:1176597,

Cosmic:1177618, Cosmic:1241344, Cosmic:1622902, Cosmic:1696753, Cosmic:2030475, Cosmic:2464666, Cosmic:2646616, Cosmic:2702440, DepMap:ACH-000961, ECACC:99040201, EGA:EGAS00001000978, ENCODE:ENCBS228AAA, ENCODE:ENCBS229AAA, ENCODE:ENCBS230AAA, GEO:GSM374972, GEO:GSM375431, GEO:GSM827370, GEO:GSM1008593, GEO:GSM1008594, GEO:GSM1669941, GEO:GSM3161714, GEO:GSM3161715, GEO:GSM6421758, GEO:GSM6421759, GEO:GSM6421760, GEO:GSM6421769, GEO:GSM6421770, GEO:GSM6421771, GEO:GSM6421772, GEO:GSM6421773, GEO:GSM6421774, GEO:GSM6421775, GEO:GSM6421776, GEO:GSM6727286, GEO:GSM6727287, IARC_TP53:1112, LINCS_HMS:50018, LINCS_LDP:LCL-1497, PharmacnoDB:Ishikawa_667_2019, Progenetix:CVCL_2529, PubChem_Cell_line:CVCL_2529, TOKU-E:3966, Ubigen:YC-D023, Wikidata:Q54898281

ID: CVCL_2529

Record Creation Time: 20220427T220641+0000

Record Last Update: 20260913T004614+0000

Ratings and Alerts

No rating or validation information has been found for Ishikawa.

No alerts have been found for Ishikawa.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Irie K, et al. (2026) Multifaceted role of POU5F1P1 in regulating its parental stem cell gene, POU5F1. iScience, 29(4), 115137.

Li X, et al. (2026) Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening. Scientific reports, 16(1).

Y?ld?r?m B, et al. (2026) Mitochondrial Injury Accompanied by Intermediate Filament Remodeling Following Lithium Chloride Exposure in 3D Endometrial Cancer Spheroids. Biomedicines, 14(3).

Tao H, et al. (2026) NSD1-Mediated PPAR? Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. Cancer research, 86(10), 2464.

Li X, et al. (2026) Lipid-Driven OLR1/FOXM1/FGF19 Axis Orchestrates Crosstalk in an Epithelial-Fibroblast Positive Feedback Promoting Progesterone Resistance in Endometrial Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(6), e11943.

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15 α -Substituted Estrone Analogues: Dual Discovery of AKR1C2/17 α -HSD1 Inhibitors and a Fluorescent 17 α -HSD1 Ligand. *Cancers*, 18(12).

Ma Y, et al. (2026) Large-Scale Quantitative Morphometry of Platelet α -Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(34), e75094.

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. *Molecular cancer therapeutics*.

Peng J, et al. (2026) CBLC-mediated ubiquitination stabilizes METTL1, enhances N7-methylguanosine modification of ESRRA, and promotes the progression of endometrial cancer. *International journal of biological macromolecules*, 369, 152809.

Bilir A, et al. (2026) Lithium Chloride-Induced Nuclear Envelope Remodeling in 3D Endometrial Cancer Spheroids. *International journal of molecular sciences*, 27(14).

Lum MA, et al. (2025) Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells. *The Journal of clinical investigation*, 135(4).

Yu H, et al. (2025) Assessment of NUDT5 in Endometrial Carcinoma: Functional Insights, Prognostic and Therapeutic Implications. *Biomedicines*, 13(5).

Liu Y, et al. (2025) NRDR Inhibits the Migration of Endometrial Cancer Cells and Affects Their Gene Expression. *Scientifica*, 2025, 2495655.

Wu Z, et al. (2025) Lipid-Metabolism-Related Gene Signature Predicts Prognosis and Immune Microenvironment Alterations in Endometrial Cancer. *Biomedicines*, 13(5).

Ramachandran D, et al. (2025) GWAS meta-analysis identifies five susceptibility loci for endometrial cancer. *EBioMedicine*, 118, 105830.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3864.

Zhang R, et al. (2025) T3-THR Signaling Governed by DIO2 Contributes to Endometrial Receptivity by Regulating Epithelial Cell Membrane Fluidity. *Endocrinology*, 166(6).

Dissanayake K, et al. (2024) Do extracellular vesicles have specific target cells?; Extracellular vesicle mediated embryo maternal communication. *Frontiers in molecular*

biosciences, 11, 1415909.

Gjorgoska M, et al. (2024) Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes. *Frontiers in endocrinology*, 15, 1404804.